Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

12.40
+0.08000.65%
Post-market: 12.400.00000.00%16:53 EDT
Volume:1.35M
Turnover:16.63M
Market Cap:956.32M
PE:5.86
High:12.47
Open:12.28
Low:12.19
Close:12.32
52wk High:17.29
52wk Low:5.70
Shares:77.12M
Float Shares:69.58M
Volume Ratio:1.13
T/O Rate:1.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.12
EPS(LYR):1.87
ROE:94.62%
ROA:1.82%
PB:4.42
PE(LYR):6.63

Loading ...

PagerDuty Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 14

Monness Sticks to Their Hold Rating for PagerDuty (PD)

TIPRANKS
·
Mar 13

PagerDuty Cut to Market Perform From Outperform by William Blair

Dow Jones
·
Mar 13

PagerDuty price target lowered to $6 from $12 at BofA

TIPRANKS
·
Mar 13

PagerDuty (PD) Gets a Hold from Craig-Hallum

TIPRANKS
·
Mar 13

Wall Street Set to Open Higher Friday as Investors Parse Inflation Data, Oil Prices

MT Newswires Live
·
Mar 13

RBC Capital Remains a Hold on PagerDuty (PD)

TIPRANKS
·
Mar 13

Top Premarket Decliners

MT Newswires Live
·
Mar 13

Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
Mar 13

PagerDuty Inc : TD Cowen Cuts Target Price to $10 From $20

THOMSON REUTERS
·
Mar 13

Truist Cuts Price Target on PagerDuty to $9 From $12, Keeps Buy Rating

MT Newswires Live
·
Mar 13

PagerDuty Shares Slide on Weak Outlook

Dow Jones
·
Mar 13

PagerDuty (PD) was downgraded to a Hold Rating at William Blair

TIPRANKS
·
Mar 13

PagerDuty Fiscal Q4 Non-GAAP Earnings, Revenue Increase

MT Newswires Live
·
Mar 13

BioVie Announces Abstract Accepted for Presentation at AD/PD 2026

GlobeNewswire
·
Mar 12

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

GlobeNewswire
·
Mar 12

CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference

GlobeNewswire
·
Mar 12

Press Release: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 12

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

GlobeNewswire
·
Mar 11

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

GlobeNewswire
·
Mar 10